Novel neuroprotective mechanisms of pramipexole, an anti-Parkinson drug, against endogenous dopamine-mediated excitotoxicity

European Journal of Pharmacology

Volumn 557, Issue 2-3, 2007, Pages 132-140

  Izumi, Yasuhiko ^a   Sawada, Hideyuki ^b   Yamamoto, Noriyuki ^a   Kume, Toshiaki ^a   Katsuki, Hiroshi ^a   Shimohama, Shun ^a   Akaike, Akinori ^a  

^a KYOTO UNIVERSITY   (Japan)

^b UTANO NATIONAL HOSPITAL   (Japan)

Author keywords

Dopamine; Glutamate toxicity; Neuroprotection; Parkinson disease

Indexed keywords

CALCIUM; DOMPERIDONE; DOPAMINE; DOPAMINE 2 RECEPTOR STIMULATING AGENT; DOPAMINE RECEPTOR; GLUTAMIC ACID; PRAMIPEXOLE; TYROSINE 3 MONOOXYGENASE;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CALCIUM TRANSPORT; CONTROLLED STUDY; DOPAMINE METABOLISM; DOPAMINERGIC NERVE CELL; DRUG MECHANISM; ENANTIOMER; ENZYME PHOSPHORYLATION; EXCITOTOXICITY; NERVE CELL; NERVE CELL NECROSIS; NEUROPROTECTION; NEUROTOXICITY; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; RAT; STIMULATION;

ANIMALS; ANTIPARKINSON AGENTS; BENZOTHIAZOLES; CELL SURVIVAL; CELLS, CULTURED; DOPAMINE; DOSE-RESPONSE RELATIONSHIP, DRUG; GLUTAMIC ACID; IMMUNOHISTOCHEMISTRY; MESENCEPHALON; NEURONS; NEUROPROTECTIVE AGENTS; PARKINSON DISEASE; RATS;

EID: 33846649595     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejphar.2006.11.011     Document Type: Article

References (40)

1. Abramova N.A., Cassarino D.S., Khan S.M., Painter T.W., and Bennett Jr. J.P. Inhibition by R(+) or S(-) pramipexole of caspase activation and cell death induced by methylpyridinium ion or beta amyloid peptide in SH-SY5Y neuroblastoma. J. Neurosci. Res. 67 (2002) 494-500
2. Bennett Jr. J.P., and Piercey M.F. Pramipexole -a new dopamine agonist for the treatment of Parkinson's disease. J. Neurol. Sci. 163 (1999) 25-31
3. Berman S.B., and Hastings T.G. Dopamine oxidation alters mitochondrial respiration and induces permeability transition in brain mitochondria: implications for Parkinson's disease. J. Neurochem. 73 (1999) 1127-1137
4. Bobrovskaya L., Dunkley P.R., and Dickson P.W. Phosphorylation of Ser19 increases both Ser40 phosphorylation and enzyme activity of tyrosine hydroxylase in intact cells. J. Neurochem. 90 (2004) 857-864
5. Carvey P.M., Pieri S., and Ling Z.D. Attenuation of levodopa-induced effects are more common than in monotherapy trials, toxicity in mesencephalic cultures by pramipexole. J. Neural Transm. 104 (1997) 209-228
6. + channels. J. Neurophysiol. 87 (2002) 1046-1056
7. Danzeisen R., Schwalenstoecker B., Gillardon F., Buerger E., Krzykalla V., Klinder K., Schild L., Hengerer B., Ludolph A.C., Dorner-Ciossek C., and Kussmaul L. Targeted antioxidative and neuroprotective properties of the dopamine agonist pramipexole and its nondopaminergic enantiomer SND919CL2x [(+)2-amino-4,5,6,7-tetrahydro-6-l propylamino-benzathiazole dihydrochloride]. J. Pharmacol. Exp. Ther. 316 (2006) 189-199
8. Dunkley P.R., Bobrovskaya L., Graham M.E., von Nagy-Felsobuki E.I., and Dickson P.W. Tyrosine hydroxylase phosphorylation: regulation and consequences. J. Neurochem. 91 (2004) 1025-1043
9. Erickson J.D., Eiden L.E., and Hoffman B.J. Expression cloning of a reserpine-sensitive vesicular monoamine transporter. Proc. Natl. Acad. Sci. U. S. A. 89 (1992) 10993-10997
10. Galzigna L., Schiappelli M.P., Rigo A., and Scarpa M. A rat brain fraction and different purified peroxidases catalyzing the formation of dopaminochrome from dopamine. Biochim. Biophys. Acta 1427 (1999) 329-336
11. Groenewegen H.J., and Berendse H.W. Connections of the subthalamic nucleus with ventral striatopallidal parts of the basal ganglia in the rat. J. Comp. Neurol. 294 (1990) 607-622
12. Gu M., Iravani M.M., Cooper J.M., King D., Jenner P., and Schapira A.H. Pramipexole protects against apoptotic cell death by non-dopaminergic mechanisms. J. Neurochem. 91 (2004) 1075-1081
13. Hubble J.P., Koller W.C., Cutler N.R., Sramek J.J., Friedman J., Goetz C., Ranhosky A., Korts D., and Elvin A. Pramipexole in patients with early Parkinson's disease. Clin. Neuropharmacol. 18 (1995) 338-347
14. Iribe Y., Moore K., Pang K.C., and Tepper J.M. Subthalamic stimulation-induced synaptic responses in substantia nigra pars compacta dopaminergic neurons in vitro. J. Neurophysiol. 82 (1999) 925-933
15. Izumi Y., Sawada H., Yamamoto N., Kume T., Katsuki H., Shimohama S., and Akaike A. Iron accelerates the conversion of dopamine-oxidized intermediates into melanin and provides protection in SH-SY5Y cells. J. Neurosci. Res. 82 (2005) 126-137
16. Izumi Y., Sawada H., Sakka N., Yamamoto N., Kume T., Katsuki H., Shimohama S., and Akaike A. p-Quinone mediates 6-hydroxydopamine-induced dopaminergic neuronal death and ferrous iron accelerates the conversion of p-quinone into melanin extracellularly. J. Neurosci. Res. 79 (2005) 849-860
17. Kitamura Y., Kosaka T., Kakimura J.I., Matsuoka Y., Kohno Y., Nomura Y., and Taniguchi T. Protective effects of the antiparkinsonian drugs talipexole and pramipexole against 1-methyl-4-phenylpyridinium-induced apoptotic death in human neuroblastoma SH-SY5Y cells. Mol. Pharmacol. 54 (1998) 1046-1054
18. Kraxner J., Hubner H., and Gmeiner P. Azepino- and diazepinoindoles: synthesis and dopamine receptor binding profiles. Arch. Pharm. 333 (2000) 287-292
19. Kumer S.C., and Vrana K.E. Intricate regulation of tyrosine hydroxylase activity and gene expression. J. Neurochem. 67 (1996) 443-462
20. Lindgren N., Xu Z.Q., Lindskog M., Herrera-Marschitz M., Goiny M., Haycock J., Goldstein M., Hokfelt T., and Fisone G. Regulation of tyrosine hydroxylase activity and phosphorylation at Ser(19) and Ser(40) via activation of glutamate NMDA receptors in rat striatum. J. Neurochem. 74 (2000) 2470-2477
21. Lindgren N., Xu Z.Q., Herrera-Marschitz M., Haycock J., Hokfelt T., and Fisone G. Dopamine D(2) receptors regulate tyrosine hydroxylase activity and phosphorylation at Ser40 in rat striatum. Eur. J. Neurosci. 13 (2001) 773-780
22. Liu Y., Peter D., Roghani A., Schuldiner S., Prive G.G., Eisenberg D., Brecha N., and Edwards R.H. A cDNA that suppresses MPP+ toxicity encodes a vesicular amine transporter. Cell 70 (1992) 539-551
23. Molho E.S., Factor S.A., Weiner W.J., Sanchez-Ramos J.R., Singer C., Shulman L., Brown D., and Sheldon C. The use of pramipexole, a novel dopamine (DA) agonist, in advanced Parkinson's disease. J. Neural Transm., Suppl. 45 (1995) 225-230
24. Nieminen A.L., Petrie T.G., Lemasters J.J., and Selman W.R. Cyclosporin A delays mitochondrial depolarization induced by N-methyl-d-aspartate in cortical neurons: evidence of the mitochondrial permeability transition. Neuroscience 75 (1996) 993-997
25. 4 receptors. J. Pharmacol. Exp. Ther. 277 (1996) 186-192
26. 123I-metaiodobenzylguanidine myocardial scintigraphy in Parkinson's disease. J. Neurol. Neurosurg. Psychiatry 67 (1999) 189-194
27. Parkinson Study Group. Dopamine transporter brain imaging to assess the effects of pramipexole vs levodopa on Parkinson disease progression. JAMA 287 (2002) 1653-1661
28. 3 receptor-preferring agonist: comparison to other dopamine receptor agonists. Eur. J. Pharmacol. 312 (1996) 35-44
29. Rodriguez M.C., Obeso J.A., and Olanow C.W. Subthalamic nucleus-mediated excitotoxicity in Parkinson's disease: a target for neuroprotection. Ann. Neurol. 44 (1998) S175-S188
30. Sawada H., Kawamura T., Shimohama S., Akaike A., and Kimura J. Different mechanisms of glutamate-induced neuronal death between dopaminergic and non-dopaminergic neurons in rat mesencephalic culture. J. Neurosci. Res. 43 (1996) 503-510
31. 2-type agonists protect mesencephalic neurons from glutamate neurotoxicity: mechanisms of neuroprotective treatment against oxidative stress. Ann. Neurol. 44 (1998) 110-119
32. Sawada H., Yamakawa K., Yamakado H., Hosokawa R., Ohba M., Miyamoto K., Kawamura T., and Shimohama S. Cocaine and phenylephrine eye drop test for Parkinson disease. JAMA 293 (2005) 932-934
33. Schneider C.S., and Mierau J. Dopamine autoreceptor agonists: resolution and pharmacological activity of 2,6-diaminotetrahydrobenzothiazole and an aminothiazole analogue of apomorphine. J. Med. Chem. 30 (1987) 494-498
34. Schuldiner S. A molecular glimpse of vesicular monoamine transporters. J. Neurochem. 62 (1994) 2067-2078
35. Schuldiner S., Steiner-Mordoch S., Yelin R., Wall S.C., and Rudnick G. Amphetamine derivatives interact with both plasma membrane and secretory vesicle biogenic amine transporters. Mol. Pharmacol. 44 (1993) 1227-1231
36. Segura-Aguilar J., Metodiewa D., and Welch C.J. Metabolic activation of dopamine o-quinones to o-semiquinones by NADPH cytochrome P450 reductase may play an important role in oxidative stress and apoptotic effects. Biochim. Biophys. Acta 1381 (1998) 1-6
37. 2 dopamine receptor activation of potassium channels is selectively decoupled by Galpha-specific GoLoco motif peptides. J. Neurochem. 92 (2005) 1408-1418
38. Whitton P.S. Glutamatergic control over brain dopamine release in vivo and in vitro. Neurosci. Biobehav. Rev. 21 (1997) 481-488
39. Xu J., Kao S.Y., Lee F.J., Song W., Jin L.W., and Yankner B.A. Dopamine-dependent neurotoxicity of alpha-synuclein: a mechanism for selective neurodegeneration in Parkinson disease. Nat. Med. 8 (2002) 600-606
40. Zou L., Jankovic J., Rowe D.B., Xie W., Appel S.H., and Le W. Neuroprotection by pramipexole against dopamine- and levodopa-induced cytotoxicity. Life Sci. 64 (1999) 1275-1285